A monoklonális antitestkezelés lehetoségei és korlátai heveny myeloid leukaemiában

Fodor Anikó, J. Demeter

Research output: Article

Abstract

Acute myeloid leukemia is still the most feared haematological malignancy, Treatment results improved a lot during the past 35 years. This improvement is due to more agressive chemotherapeutic protocolls, better supportive therapy as well as in a certain cases to the use of stem cell transplantation. The development of monoclonal antibodies offers a targeted approach in the treatment, their efficacy can be improved with the addition of cytostatic drugs or radioisotopes. The CD33 antigen, expressed on the surface of myeloid blasts is a suitable target. Application of the non-conjugated anti-CD33 monoclonal antibody, lintuzumab or of the anti-CD33 monoclonal antibody conjugated with a toxin, gemtuzumab ozogamicin (GO) result in survival advantage in elderly patients with AML In the last decade GO has been applied in several combinations both in elderly and in young patients, in the primary as well as in the relapsed setting. Experience with treatment using monoclonal antibodies (anti CD33, antiCD45, anti CD66) combined with radioisotopes as part of conditioning treatment before stem cell transplantation is also growing. The development of new diagnostic possibilities and new knowledge on molecular genetic abnormalities in the background of the individual AML subtypes open new perspectives in drug development. Real success still remains to be awaited.

Original languageHungarian
Pages (from-to)205-210
Number of pages6
JournalOrvoskepzes
Volume84
Issue number3
Publication statusPublished - 2009

Fingerprint

Acute Myeloid Leukemia
Monoclonal Antibodies
Stem Cell Transplantation
Radioisotopes
Sialic Acid Binding Ig-like Lectin 3
Cytostatic Agents
Hematologic Neoplasms
Therapeutics
Molecular Biology
Survival
Pharmaceutical Preparations
gemtuzumab

Keywords

  • Acute myeloid leukemia
  • Gemtuzumab ozogamicin
  • Monoclonal antibody
  • Radio-immunotherapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A monoklonális antitestkezelés lehetoségei és korlátai heveny myeloid leukaemiában. / Anikó, Fodor; Demeter, J.

In: Orvoskepzes, Vol. 84, No. 3, 2009, p. 205-210.

Research output: Article

@article{3129c65cb02548ee985d0b18fa83d9a6,
title = "A monoklon{\'a}lis antitestkezel{\'e}s lehetos{\'e}gei {\'e}s korl{\'a}tai heveny myeloid leukaemi{\'a}ban",
abstract = "Acute myeloid leukemia is still the most feared haematological malignancy, Treatment results improved a lot during the past 35 years. This improvement is due to more agressive chemotherapeutic protocolls, better supportive therapy as well as in a certain cases to the use of stem cell transplantation. The development of monoclonal antibodies offers a targeted approach in the treatment, their efficacy can be improved with the addition of cytostatic drugs or radioisotopes. The CD33 antigen, expressed on the surface of myeloid blasts is a suitable target. Application of the non-conjugated anti-CD33 monoclonal antibody, lintuzumab or of the anti-CD33 monoclonal antibody conjugated with a toxin, gemtuzumab ozogamicin (GO) result in survival advantage in elderly patients with AML In the last decade GO has been applied in several combinations both in elderly and in young patients, in the primary as well as in the relapsed setting. Experience with treatment using monoclonal antibodies (anti CD33, antiCD45, anti CD66) combined with radioisotopes as part of conditioning treatment before stem cell transplantation is also growing. The development of new diagnostic possibilities and new knowledge on molecular genetic abnormalities in the background of the individual AML subtypes open new perspectives in drug development. Real success still remains to be awaited.",
keywords = "Acute myeloid leukemia, Gemtuzumab ozogamicin, Monoclonal antibody, Radio-immunotherapy",
author = "Fodor Anik{\'o} and J. Demeter",
year = "2009",
language = "Hungarian",
volume = "84",
pages = "205--210",
journal = "Orvoskepzes",
issn = "0030-6037",
publisher = "Semmelweis Kiado",
number = "3",

}

TY - JOUR

T1 - A monoklonális antitestkezelés lehetoségei és korlátai heveny myeloid leukaemiában

AU - Anikó, Fodor

AU - Demeter, J.

PY - 2009

Y1 - 2009

N2 - Acute myeloid leukemia is still the most feared haematological malignancy, Treatment results improved a lot during the past 35 years. This improvement is due to more agressive chemotherapeutic protocolls, better supportive therapy as well as in a certain cases to the use of stem cell transplantation. The development of monoclonal antibodies offers a targeted approach in the treatment, their efficacy can be improved with the addition of cytostatic drugs or radioisotopes. The CD33 antigen, expressed on the surface of myeloid blasts is a suitable target. Application of the non-conjugated anti-CD33 monoclonal antibody, lintuzumab or of the anti-CD33 monoclonal antibody conjugated with a toxin, gemtuzumab ozogamicin (GO) result in survival advantage in elderly patients with AML In the last decade GO has been applied in several combinations both in elderly and in young patients, in the primary as well as in the relapsed setting. Experience with treatment using monoclonal antibodies (anti CD33, antiCD45, anti CD66) combined with radioisotopes as part of conditioning treatment before stem cell transplantation is also growing. The development of new diagnostic possibilities and new knowledge on molecular genetic abnormalities in the background of the individual AML subtypes open new perspectives in drug development. Real success still remains to be awaited.

AB - Acute myeloid leukemia is still the most feared haematological malignancy, Treatment results improved a lot during the past 35 years. This improvement is due to more agressive chemotherapeutic protocolls, better supportive therapy as well as in a certain cases to the use of stem cell transplantation. The development of monoclonal antibodies offers a targeted approach in the treatment, their efficacy can be improved with the addition of cytostatic drugs or radioisotopes. The CD33 antigen, expressed on the surface of myeloid blasts is a suitable target. Application of the non-conjugated anti-CD33 monoclonal antibody, lintuzumab or of the anti-CD33 monoclonal antibody conjugated with a toxin, gemtuzumab ozogamicin (GO) result in survival advantage in elderly patients with AML In the last decade GO has been applied in several combinations both in elderly and in young patients, in the primary as well as in the relapsed setting. Experience with treatment using monoclonal antibodies (anti CD33, antiCD45, anti CD66) combined with radioisotopes as part of conditioning treatment before stem cell transplantation is also growing. The development of new diagnostic possibilities and new knowledge on molecular genetic abnormalities in the background of the individual AML subtypes open new perspectives in drug development. Real success still remains to be awaited.

KW - Acute myeloid leukemia

KW - Gemtuzumab ozogamicin

KW - Monoclonal antibody

KW - Radio-immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=82455216852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82455216852&partnerID=8YFLogxK

M3 - Article

VL - 84

SP - 205

EP - 210

JO - Orvoskepzes

JF - Orvoskepzes

SN - 0030-6037

IS - 3

ER -